scholarly journals Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model

2015 ◽  
Vol 19 (11) ◽  
pp. 2540-2548 ◽  
Author(s):  
Ferdinando Squitieri ◽  
Alba Di Pardo ◽  
Mariagrazia Favellato ◽  
Enrico Amico ◽  
Vittorio Maglione ◽  
...  
Keyword(s):  
Mouse Model ◽  
Huntington Disease ◽  
Motor Performance ◽  
Neuroprotective Effects ◽  
Dopamine Stabilizer

Neuroprotective Effects of a GLP-2 Analogue in the MPTP Parkinson’s Disease Mouse Model

2021 ◽  
pp. 1-15
Author(s):  
Zijuan Zhang ◽  
Li Hao ◽  
Ming Shi ◽  
Ziyang Yu ◽  
Simai Shao ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Substantia Nigra ◽  
Mouse Model ◽  
Neurodegenerative Disorder ◽  
Enzyme Linked Immunosorbent Assay ◽  
Protective Effects ◽  
Neuroprotective Effects ◽  
Expression Levels ◽  
Dual Agonist

Background: Glucagon-like peptide 2 (GLP-2) is a peptide hormone derived from the proglucagon gene expressed in the intestines, pancreas and brain. Some previous studies showed that GLP-2 improved aging and Alzheimer’s disease related memory impairments. Parkinson’s disease (PD) is a progressive neurodegenerative disorder, and to date, there is no particular medicine reversed PD symptoms effectively. Objective: The aim of this study was to evaluate neuroprotective effects of a GLP-2 analogue in the 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) PD mouse model. Methods: In the present study, the protease resistant Gly(2)-GLP-2 (50 nmol/kg ip.) analogue has been tested for 14 days by behavioral assessment, transmission electron microscope, immunofluorescence histochemistry, enzyme-linked immunosorbent assay and western blot in an acute PD mouse model induced by MPTP. For comparison, the incretin receptor dual agonist DA5-CH was tested in a separate group. Results: The GLP-2 analogue treatment improved the locomotor and exploratory activity of mice, and improved bradykinesia and movement imbalance of mice. Gly(2)-GLP-2 treatment also protected dopaminergic neurons and restored tyrosine hydroxylase expression levels in the substantia nigra. Gly(2)-GLP-2 furthermore reduced the inflammation response as seen in lower microglia activation, and decreased NLRP3 and interleukin-1β pro-inflammatory cytokine expression levels. In addition, the GLP-2 analogue improved MPTP-induced mitochondrial dysfunction in the substantia nigra. The protective effects were comparable to those of the dual agonist DA5-CH. Conclusion: The present results demonstrate that Gly(2)-GLP-2 can attenuate NLRP3 inflammasome-mediated inflammation and mitochondrial damage in the substantia nigra induced by MPTP, and Gly(2)-GLP-2 shows neuroprotective effects in this PD animal model.

scholarly journals Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease

2005 ◽  
Vol 95 (1) ◽  
pp. 210-220 ◽  
Author(s):  
Jeremy M. Van Raamsdonk ◽  
Jacqueline Pearson ◽  
Craig D. C. Bailey ◽  
Daniel A. Rogers ◽  
Gail V. W. Johnson ◽  
...  
Keyword(s):  
Mouse Model ◽  
Huntington Disease ◽  
Yac128 Mouse

scholarly journals Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease

2005 ◽  
Vol 14 (24) ◽  
pp. 3823-3835 ◽  
Author(s):  
Jeremy M. Van Raamsdonk ◽  
Zoe Murphy ◽  
Elizabeth J. Slow ◽  
Blair R. Leavitt ◽  
Michael R. Hayden
Keyword(s):  
Mouse Model ◽  
Nuclear Localization ◽  
Huntington Disease ◽  
Mutant Huntingtin ◽  
Yac128 Mouse
Sign in / Sign up

Export Citation Format

Share Document